ALL MARKETS
FTSE 100
FTSE 250
AIM MARKET


Angle PLC.
151 announcements.
Time Date Ticker Company Announcement
07:00 07-09-2021 AGL Angle PLC
Notice of Interim Results and Webcast
07:00 24-08-2021 AGL Angle PLC
Director/PDMR Shareholding
07:00 09-08-2021 AGL Angle PLC
Study highlights superior performance of Parsortix
13:17 06-08-2021 AGL Angle PLC
Issue of Equity
15:13 03-08-2021 AGL Angle PLC
Issue of Equity
07:00 28-07-2021 AGL Angle PLC
Contract secured for bespoke assay development
07:00 09-07-2021 AGL Angle PLC
Harvesting CTCs from brain metastasis patients
10:45 02-07-2021 AGL Angle PLC
Issue of Equity
15:44 30-06-2021 AGL Angle PLC
Result of AGM
07:00 25-06-2021 AGL Angle PLC
Result of Accelerated Bookbuild
11:42 18-06-2021 AGL Angle PLC
Annual General Meeting update
07:00 18-06-2021 AGL Angle PLC
ctDNA and CTCs have differences in EGFR mutations
07:00 04-06-2021 AGL Angle PLC
Update on submission for FDA clearance
07:00 01-06-2021 AGL Angle PLC
Potential to prevent breast cancer relapse
07:00 20-05-2021 AGL Angle PLC
Parsortix demonstrates oesophageal cancer utility
16:37 19-05-2021 AGL Angle PLC
Exercise of options and total voting rights
07:00 11-05-2021 AGL Angle PLC
Parsortix study uncovers targets in TNBC patients
11:22 30-04-2021 AGL Angle PLC
Exercise of options and total voting rights
07:00 29-04-2021 AGL Angle PLC
Preliminary Results
07:00 26-04-2021 AGL Angle PLC
Ovarian cancer study patient enrolment completed
14:05 19-04-2021 AGL Angle PLC
Second Price Monitoring Extn
14:00 19-04-2021 AGL Angle PLC
Price Monitoring Extension
11:05 19-04-2021 AGL Angle PLC
Second Price Monitoring Extn
11:00 19-04-2021 AGL Angle PLC
Price Monitoring Extension
07:00 16-04-2021 AGL Angle PLC
First large-scale pharma services contract secured
16:10 15-04-2021 AGL Angle PLC
Notice of Preliminary Results and Webcast
07:00 12-04-2021 AGL Angle PLC
ANGLE's Parsortix system showcased at AACR 2021
07:00 30-03-2021 AGL Angle PLC
Global launch of clinical services laboratories
07:00 04-03-2021 AGL Angle PLC
Update on submission for FDA clearance
07:00 18-02-2021 AGL Angle PLC
Parsortix-harvested CTCs uncover novel biomarker
07:00 08-02-2021 AGL Angle PLC
Parsortix: Dynamic assessment of patient response
07:00 29-01-2021 AGL Angle PLC
Parsortix demonstrates high capture rate of CTCs
13:00 26-01-2021 AGL Angle PLC
Holding(s) in Company
07:00 20-01-2021 AGL Angle PLC
Research confirms high performance of Parsortix
07:00 12-01-2021 AGL Angle PLC
Change of Auditor
07:00 05-01-2021 AGL Angle PLC
Issue of Equity
07:00 09-12-2020 AGL Angle PLC
Parsortix can capture single cancer cell in sample
16:18 20-11-2020 AGL Angle PLC
Holding(s) in Company
16:51 18-11-2020 AGL Angle PLC
Holding(s) in Company
10:46 13-11-2020 AGL Angle PLC
Result of General Meeting
14:54 03-11-2020 AGL Angle PLC
Director/PDMR Shareholding
07:00 29-10-2020 AGL Angle PLC
Interim Results
18:28 27-10-2020 AGL Angle PLC
Result of Placing & Notice of General Meeting
07:00 27-10-2020 AGL Angle PLC
Accelerated bookbuild to raise up to 20m
07:00 20-10-2020 AGL Angle PLC
Submission accepted by FDA for substantive review
07:00 28-09-2020 AGL Angle PLC
ANGLE announces completion of FDA submission
07:00 28-09-2020 AGL Angle PLC
Issue of LTIP Options and Share Options
07:00 23-09-2020 AGL Angle PLC
Potential treatment strategy to limit metastasis
15:35 11-09-2020 AGL Angle PLC
Holding(s) in Company
15:30 11-09-2020 AGL Angle PLC
Holding(s) in Company
13:49 02-09-2020 AGL Angle PLC
Notification of Interim Results and Webcast
10:00 02-09-2020 AGL Angle PLC
Holding(s) in Company
15:13 27-08-2020 AGL Angle PLC
Result of 2020 Annual General Meeting
09:30 18-08-2020 AGL Angle PLC
Holding(s) in Company
07:00 14-08-2020 AGL Angle PLC
Parsortix use to assess response to immunotherapy
12:20 06-08-2020 AGL Angle PLC
Holding(s) in Company
07:00 05-08-2020 AGL Angle PLC
Notice of AGM and Posting of Annual Report
07:00 20-07-2020 AGL Angle PLC
Study: Parsortix use in metastatic breast cancer
17:35 08-07-2020 AGL Angle PLC
Holding(s) in Company
17:30 08-07-2020 AGL Angle PLC
Holding(s) in Company
17:30 08-07-2020 AGL Angle PLC
Holding(s) in Company
07:00 25-06-2020 AGL Angle PLC
Preliminary Results
07:00 22-06-2020 AGL Angle PLC
Blood donations recommenced for FDA studies
07:00 29-05-2020 AGL Angle PLC
Notice of Results
07:00 12-05-2020 AGL Angle PLC
CTC potential as biomarker in MET inhibitor trials
07:00 04-05-2020 AGL Angle PLC
Leading cancer centre publishes Parsortix workflow
07:00 28-04-2020 AGL Angle PLC
Business Update
07:00 17-04-2020 AGL Angle PLC
Parsortix performance in head and neck cancer
07:00 31-03-2020 AGL Angle PLC
COVID-19 BUSINESS IMPACT UPDATE
07:00 03-03-2020 AGL Angle PLC
Assessing risk of brain metastasis in lung cancer
07:00 27-02-2020 AGL Angle PLC
Parsortix outperforms other CTC systems in RCC
07:00 25-02-2020 AGL Angle PLC
ANGLE announce Tri-Con presentation with BioView
07:00 17-02-2020 AGL Angle PLC
Data demonstrates key advantages of Parsortix
07:00 11-02-2020 AGL Angle PLC
Study demonstrates Parsortix potential in melanoma
09:10 03-02-2020 AGL Angle PLC
Issue of Equity
07:00 30-01-2020 AGL Angle PLC
Change of accounting reference date
07:00 30-01-2020 AGL Angle PLC
Interim Results
07:00 22-01-2020 AGL Angle PLC
Successful face-to-face meeting with FDA
12:33 08-01-2020 AGL Angle PLC
Notice of Results
09:55 23-12-2019 AGL Angle PLC
Issue of Equity
07:00 07-11-2019 AGL Angle PLC
Cancer centre shows Parsortix use in melanoma
14:44 30-10-2019 AGL Angle PLC
Result of AGM
07:00 30-10-2019 AGL Angle PLC
Q-submission to FDA containing headline data
07:00 08-10-2019 AGL Angle PLC
Notice of AGM
07:00 04-10-2019 AGL Angle PLC
European patent granted for megakaryocyte analysis
07:00 13-09-2019 AGL Angle PLC
Use of Parsortix in head and neck cancer
07:00 10-09-2019 AGL Angle PLC
Research with Parsortix in prostate cancer
07:00 04-09-2019 AGL Angle PLC
Parsortix for Neuroendocrine Analysis in SCLC
07:00 29-08-2019 AGL Angle PLC
Initiation of Ovarian Cancer Study
07:00 31-07-2019 AGL Angle PLC
Prelim Results for the year ended 30 April 2019
07:00 22-07-2019 AGL Angle PLC
Use of Parsortix for single cell analysis of CTCs
09:19 16-07-2019 AGL Angle PLC
Holding(s) in Company
10:22 12-07-2019 AGL Angle PLC
Result of General Meeting anf Total Voting Rights
13:37 28-06-2019 AGL Angle PLC
Notice of Preliminary Results and Webcast
13:08 28-06-2019 AGL Angle PLC
Holding(s) in Company
17:19 25-06-2019 AGL Angle PLC
Result of Placing
08:02 25-06-2019 AGL Angle PLC
Accelerated bookbuild to raise £18.0m
07:00 21-06-2019 AGL Angle PLC
Parsortix used to investigate immunotherapy target
07:00 05-06-2019 AGL Angle PLC
Completion of Ovarian Cancer Pre-Study
07:00 31-05-2019 AGL Angle PLC
Positive Results from FDA Clinical Study
07:00 26-04-2019 AGL Angle PLC
IMMUNE SUPPRESSOR CELLS PROMOTE METASTASIS
07:00 18-04-2019 AGL Angle PLC
Parsortix used in new cancer assessment technique
07:00 12-04-2019 AGL Angle PLC
LUNG CANCER STUDY USES ANGLE'S PARSORTIX SYSTEM
07:00 04-04-2019 AGL Angle PLC
AACR 2019
07:00 11-03-2019 AGL Angle PLC
Holding(s) in Company
07:00 07-03-2019 AGL Angle PLC
ENROLMENT COMPLETE FOR FDA CLINICAL STUDY
07:00 28-02-2019 AGL Angle PLC
FIRST SUBJECTS ENROLLED IN OVARIAN CANCER STUDY
07:00 25-02-2019 AGL Angle PLC
CUSTOMER DEMONSTRATES NEW USE FOR PARSORTIX
07:00 11-02-2019 AGL Angle PLC
Research into role of immune cells in cancer
07:00 31-01-2019 AGL Angle PLC
Interim Results
07:00 29-01-2019 AGL Angle PLC
NEW APPLICATION FOR PARSORTIX IN CANCER ANALYSIS
14:05 11-01-2019 AGL Angle PLC
Second Price Monitoring Extn
14:00 11-01-2019 AGL Angle PLC
Price Monitoring Extension
11:05 11-01-2019 AGL Angle PLC
Second Price Monitoring Extn
11:00 11-01-2019 AGL Angle PLC
Price Monitoring Extension
09:05 11-01-2019 AGL Angle PLC
Second Price Monitoring Extn
09:00 11-01-2019 AGL Angle PLC
Price Monitoring Extension
16:41 10-01-2019 AGL Angle PLC
Second Price Monitoring Extn
16:36 10-01-2019 AGL Angle PLC
Price Monitoring Extension
16:01 10-01-2019 AGL Angle PLC
BREAKTHROUGH CANCER RESEARCH USING PARSORTIX
07:00 09-01-2019 AGL Angle PLC
Notice of Results
07:00 21-12-2018 AGL Angle PLC
Issue of LTIP Options and Share Options
07:00 28-11-2018 AGL Angle PLC
LEADING US HEMATOPATHOLOGIST APPOINTED AS ADVISOR
17:10 13-11-2018 AGL Angle PLC
Holding(s) in Company
07:00 05-11-2018 AGL Angle PLC
Acquisition of outstanding shares
14:00 02-11-2018 AGL Angle PLC
Price Monitoring Extension
07:00 01-11-2018 AGL Angle PLC
Appointment of Dr Jan Groen as NED
16:21 30-10-2018 AGL Angle PLC
Result of AGM
07:00 29-10-2018 AGL Angle PLC
PARSORTIX SHOWS CAPABILITY TO HARVEST FETAL CELLS
07:00 25-10-2018 AGL Angle PLC
Good Progress with FDA Studies
07:00 09-10-2018 AGL Angle PLC
Notice of AGM
07:00 28-08-2018 AGL Angle PLC
Parsortix shows evidence of CTCs in glioblastoma
07:00 25-07-2018 AGL Angle PLC
Preliminary Results for year ended 30 April 2018
17:42 24-07-2018 AGL Angle PLC
EIS/VCT Advance Assurance and Total Voting Rights
10:34 18-07-2018 AGL Angle PLC
Result of General Meeting
07:00 02-07-2018 AGL Angle PLC
Notice of Preliminary Results
14:58 25-06-2018 AGL Angle PLC
Close of Accelerated Bookbuild
07:50 25-06-2018 AGL Angle PLC
Proposed Placing of New Ordinary Shares
07:00 04-06-2018 AGL Angle PLC
ENCOURAGING PROGRESS IN ANG-002 FDA CLINICAL STUDY
07:00 08-01-2018 AGL Angle PLC
ANGLE plc:Prostate cancer ARV7 treatment biomarker
10:16 10-01-2018 AGL Angle PLC
Notice of Results
07:00 16-01-2018 AGL Angle PLC
WEBINAR:USING PARSORTIX TO TEST DRUGS ON LIVE CTCS
07:00 31-01-2018 AGL Angle PLC
Interim Results
07:00 06-02-2018 AGL Angle PLC
ANGLE plc: RESEARCH GRANT FROM ABBOTT
16:35 26-03-2018 AGL Angle PLC
Price Monitoring Extension
07:00 26-03-2018 AGL Angle PLC
Research Update
07:00 05-04-2018 AGL Angle PLC
First patient enrolled in FDA study
07:00 19-04-2018 AGL Angle PLC
Breakthrough Research with Parsortix
07:00 19-04-2018 AGL Angle PLC
Parsortix in multiple presentations at AACR
07:00 03-05-2018 AGL Angle PLC
Angle & QIAGEN Poster
07:00 14-05-2018 AGL Angle PLC
Leading cancer surgeon appointed